Description

Established in Tokyo, Japan, in 1955, Zeria Pharmaceutical Co., Ltd. operates internationally, engaging in the development, production, and global distribution of a broad spectrum of products. Its core business encompasses pharmaceuticals, non-pharmaceutical items, veterinary medicines, agricultural and industrial chemicals, and laboratory reagents. Beyond these, the company's extensive portfolio also includes cosmetics, health foods, various beverages (alcoholic and soft drinks), food additives, livestock feed, and hygienic goods. They further extend into medical and health-related equipment, facilities, beauty appliances, and analytical instruments. A significant portion of their pharmaceutical offerings focuses on gastrointestinal health, encompassing treatments for conditions such as functional dyspepsia, ulcerative colitis, Crohn's disease, gastritis, and ulcers, alongside zinc-based anti-ulcer medications, oral bowel cleansers, and laxatives. Additionally, their specialized drug pipeline features treatments for hypophosphatemia, long-acting calcium channel blockers, oral non-steroidal anti-inflammatory drugs (NSAIDs), and agents to combat leukopenia post-radiotherapy. They also offer sclerosing agents for varicose veins, anti-inflammatory topical enhancers for blood circulation, non-steroidal anti-inflammatory eye drops, absorbable topical hemostatic products, and proton pump inhibitors. For consumer health, Zeria Pharmaceutical provides a wide selection of over-the-counter remedies and wellness products. These range from nutritional supplements and cold and ophthalmic solutions to anti-inflammatory and analgesic medications, treatments for hemorrhoids and skin conditions, quasi-drugs, and cosmetics. They also market nutrient tonics and food items specifically designed for health benefits. The company, initially known as Zeria Yakusho Kenkyusho Co., Ltd., adopted its current name, Zeria Pharmaceutical Co., Ltd., in May 1970.